Abstract: A telescopic sight has an objective lens system, an eyepiece lens system and an inversion system disposed in the optical path between the objective lens system and the eye piece lens system and pivotably supported by means of a height adjustment device, a lateral adjustment device, a reticle, and a projection means disposed at the end of the inversion system on the eyepiece side. The inversion system generates an image plane at the end on the eyepiece side having a perpendicular alignment relative to the inversion system optical axis. The projection means generates a projection in the field of view of the sight, which is located in a projection plane, wherein the projection plane is aligned perpendicularly relative to the optical axis and in the image plane of the inversion system. A display means assigned to the inversion system generates information and/or a target mark in the projection plane.

Abstract: The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.

Abstract: The present invention relates to the use of a DNA expression construct comprising a dumbbell-shaped circular strand of deoxyribonucleic acids and provides such a construct with a double-stranded stem and single-stranded loops located at both ends of the stem, wherein the stem comprises complementary deoxyribonucleic acids of the circular strand with a promotor sequence, a coding sequence and a termination signal to be administered by jet injection for the treatment of cancer.

Abstract: A vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of defined tumor diseases, and a method for the making of such vaccine is disclosed. The tumor cells were previously transfected ex vivo with expression constructs encoding cytokines and co-stimulatory factors.

Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Abstract: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.

Abstract: The invention relates to a telescopic sight for a firearm which has a telescope body (2) with an eyepiece (3) and an objective (4) and an illuminating device for an illuminated graticule, wherein the illuminating device has a control electronics unit (22) and an energy store (23). Further, the invention relates to an illuminating module (7) for a telescopic sight of this kind and a programming adapter (30) for an illuminating module of this kind. In order to enable an individual adjustment of the illumination characteristic, the control electronics unit (22) is arranged in a housing (10) which can be releasably accommodated in a saddle (8) on an outside of the telescopic sight (1), wherein the housing (10) with the control electronics unit (22) forms an independently manageable illuminating module (7) which can be fitted into a programming adapter (30).

Abstract: A telescopic sight has an objective lens system, an eyepiece lens system and an inversion system disposed in the optical path between the objective lens system and the eye piece lens system and pivotably supported by means of a height adjustment device, a lateral adjustment device, a reticle, and a projection means disposed at the end of the inversion system on the eyepiece side. The inversion system generates an image plane at the end on the eyepiece side having a perpendicular alignment relative to the inversion system optical axis. The projection means generates a projection in the field of view of the sight, which is located in a projection plane, wherein the projection plane is aligned perpendicularly relative to the optical axis and in the image plane of the inversion system. A display means allocated to the inversion system generates information and/or an a target mark in the projection plane.

Abstract: The invention relates to a telescopic sight for a firearm which has a telescope body (2) with an eyepiece (3) and an objective (4) and an illuminating device for an illuminated graticule, wherein the illuminating device has a control electronics unit (22) and an energy store (23). Further, the invention relates to an illuminating module (7) for a telescopic sight of this kind and a programming adapter (30) for an illuminating module of this kind. In order to enable an individual adjustment of the illumination characteristic, the control electronics unit (22) is arranged in a housing (10) which can be releasably accommodated in a saddle (8) on an outside of the telescopic sight (1), wherein the housing (10) with the control electronics unit (22) forms an independently manageable illuminating module (7) which can be fitted into a programming adapter (30).

Abstract: The present invention relates to the use of a DNA expression construct comprising a dumbbell-shaped circular strand of deoxyribonucleic acids and provides such a construct with a double-stranded stem and single-stranded loops located at both ends of the stem, wherein the stem comprises complementary deoxyribonucleic acids of the circular strand with a promotor sequence, a coding sequence and a termination signal to be administered by jet injection for the treatment of cancer.

Abstract: The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other.

Abstract: Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans and vertebrates.

Abstract: The invention relates to a multimeric, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a production method therefor, and to a vaccine containing said multimeric, non-coding nucleic acid molecule. Said multimeric, non-coding nucleic acid molecules can be non-coding nucleic acid molecules that consist of at least two of said molecules (dimer) or assemblies of several non-coding nucleic acid molecules.

Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Abstract: The invention relates to a method for the in vitro investigation of the effect of substances in in vivo processes and an in vitro detection method for the identification of immunomodulating compounds and/or the detection of the effect of immunomodulating compounds and the identification of apoptosis-inducing and/or necrosis-inducing compounds mediated by the immune system in in vivo processes. The methods according to the invention are particularly suitable for investigating effects of substances on cells, which are mediated by the immune system. Furthermore, the method according to the invention is suitable for in vitro monitoring of the in vivo effects before, during and/or after the administration of immunomodulating compounds and of apoptosis-inducing and/or necrosis-inducing compounds.

Abstract: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.

Abstract: A sensor arrangement, in particular as part of a reflection light barrier, includes a carrier as well as a photodiode, a first light emitting diode for emitting a measuring light beam, and a second light emitting diode for emitting a reference light beam, in particular a reference light beam pulsed offset in time with respect to the measuring light beam, arranged on the carrier, and further includes a light permeable housing enclosing the photodiode and the two light emitting diodes. The second light emitting diode is arranged on the carrier and in the housing such that the reference light emitted by it is essentially not incident on the side of the photodiode but rather is reflected internally in the housing to be incident onto an upper surface of the photodiode.

Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Abstract: A substituted, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, a method for the production thereof, and a vaccine containing said substituted, non-coding nucleic acid molecule. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.